Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Overview of dermatitis

INTRODUCTION

The terms "dermatitis" and "eczema" are frequently used interchangeably. When the term "eczema" is used alone, it usually refers to atopic dermatitis (atopic eczema). "Eczematous" also connotes some scaling, crusting, or serous oozing as opposed to mere erythema. The term "dermatitis" is typically used with qualifiers (eg, "contact dermatitis") to describe several different skin disorders, the most common of which are discussed in this review. Atopic dermatitis is discussed separately. (See "Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)".)

SEBORRHEIC DERMATITIS

Seborrheic dermatitis is a common problem of unknown etiology. Approximately 1 to 3 percent of adults have seborrheic dermatitis [1]. The term is derived from the distribution of this disorder, in which erythematous, scaly patches develop in areas that are rich in sebaceous glands, such as the scalp, face, and upper trunk. The term "seborrhea" refers to excess oil secretion, although this finding is not uniformly present in patients with seborrheic dermatitis [2,3].

In infants, seborrheic dermatitis of the scalp is often called "cradle cap." (See "Cradle cap and seborrheic dermatitis in infants", section on 'Clinical manifestations'.)

Pathogenesis — The cause of seborrheic dermatitis is not completely understood. Evidence supports a causal role of the skin saprophytic species of Malassezia (formerly Pityrosporum ovale), which has been shown to colonize the skin of patients with this disorder [4]. A host reaction to Malassezia yeasts or their metabolites is thought to contribute to the inflammatory response seen in seborrheic dermatitis [5].

Malassezia are lipid-dependent organisms which proliferate in sebum and are normal residents of the skin flora. Although increased numbers of yeasts have been reported in patients with seborrheic dermatitis [6], the number of Malassezia organisms present on the skin does not always correlate with the presence or severity of the disorder [3,5]. However, a contribution of Malassezia to the pathogenesis of seborrheic dermatitis is supported by the clinical response to antifungal therapies.

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Mar 5, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13.
  2. Burton JL, Pye RJ. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed) 1983; 286:1169.
  3. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387.
  4. Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc 2007; 12:15.
  5. DeAngelis YM, Gemmer CM, Kaczvinsky JR, et al. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc 2005; 10:295.
  6. McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol 1975; 64:401.
  7. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29:1008.
  8. Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141:47.
  9. Satchell AC, Saurajen A, Bell C, Barnetson RS. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol 2002; 47:852.
  10. van der Valk PG, de Groot AC, Bruynzeel DP, et al. [Allergic contact eczema due to 'tea tree' oil]. Ned Tijdschr Geneeskd 1994; 138:823.
  11. Knight TE, Hausen BM. Melaleuca oil (tea tree oil) dermatitis. J Am Acad Dermatol 1994; 30:423.
  12. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356:479.
  13. Piérard GE, Piérard-Franchimont C, Van Cutsem J, et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol 1991; 30:806.
  14. Van Cutsem J, Van Gerven F, Fransen J, et al. The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs. J Am Acad Dermatol 1990; 22:993.
  15. Dupuy P, Maurette C, Amoric JC, et al. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144:1033.
  16. Scaparro E, Quadri G, Virno G, et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; 144:854.
  17. Parsad D, Pandhi R, Negi KS, Kumar B. Topical metronidazole in seborrheic dermatitis--a double-blind study. Dermatology 2001; 202:35.
  18. Ozcan H, Seyhan M, Yologlu S. Is metronidazole 0.75% gel effective in the treatment of seborrhoeic dermatitis? A double-blind, placebo controlled study. Eur J Dermatol 2007; 17:313.
  19. Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol 2007; 21:345.
  20. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57:257.
  21. Eisenstat BA, Wormser GP. Seborrheic dermatitis and butterfly rash in AIDS. N Engl J Med 1984; 311:189.
  22. Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985; 13:947.
  23. Wikler JR, Nieboer C, Willemze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol 1992; 27:37.
  24. Chen TM, Fitzpatrick JE. Unilateral seborrheic dermatitis after decompression of Chiari I malformation and syringomyelia. J Am Acad Dermatol 2006; 55:356.
  25. BETTLEY FR, MARTEN RH. Unilateral seborrheic dermatitis following a nerve lesion. AMA Arch Derm 1956; 73:110.
  26. Rosen RH, Freeman S. Occupational contact dermatitis in New South Wales. Australas J Dermatol 1992; 33:1.
  27. Belsito DV. Occupational contact dermatitis: etiology, prevalence, and resultant impairment/disability. J Am Acad Dermatol 2005; 53:303.
  28. Templet JT, Hall S, Belsito DV. Etiology of hand dermatitis among patients referred for patch testing. Dermatitis 2004; 15:25.
  29. Rietschel RL, Fowler JF, Warshaw EM, et al. Detection of nickel sensitivity has increased in North American patch-test patients. Dermatitis 2008; 19:16.
  30. Wilkinson SM. Hypersensitivity to topical corticosteroids. Clin Exp Dermatol 1994; 19:1.
  31. Wilkinson SM, English JS, Mattey DL. In vitro evidence of delayed-type hypersensitivity to hydrocortisone. Contact Dermatitis 1993; 29:241.
  32. de Pádua CA, Schnuch A, Nink K, et al. Allergic contact dermatitis to topical drugs--epidemiological risk assessment. Pharmacoepidemiol Drug Saf 2008; 17:813.
  33. Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008; 58:1.
  34. Warshaw EM, Schram SE, Belsito DV, et al. Shoe allergens: retrospective analysis of cross-sectional data from the north american contact dermatitis group, 2001-2004. Dermatitis 2007; 18:191.
  35. Belsito DV, Fransway AF, Fowler JF Jr, et al. Allergic contact dermatitis to detergents: a multicenter study to assess prevalence. J Am Acad Dermatol 2002; 46:200.
  36. Johnson WC, O'Hara ET, Corey C, et al. Venous stasis ulceration. Effectiveness of subfascial ligation. Arch Surg 1985; 120:797.
  37. Kulozik M, Powell SM, Cherry G, Ryan TJ. Contact sensitivity in community-based leg ulcer patients. Clin Exp Dermatol 1988; 13:82.
  38. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 1996; 276:972.
  39. Kikta MJ, Schuler JJ, Meyer JP, et al. A prospective, randomized trial of Unna's boots versus hydroactive dressing in the treatment of venous stasis ulcers. J Vasc Surg 1988; 7:478.
  40. Nedorost S. Clinical patterns of hand and foot dermatitis: emphasis on rubber and chromate allergens. Dermatol Clin 2009; 27:281.
  41. Saripalli YV, Achen F, Belsito DV. The detection of clinically relevant contact allergens using a standard screening tray of twenty-three allergens. J Am Acad Dermatol 2003; 49:65.
  42. Saary J, Qureshi R, Palda V, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol 2005; 53:845.
  43. Belsito D, Wilson DC, Warshaw E, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006; 55:40.
  44. Agner T. Noninvasive measuring methods for the investigation of irritant patch test reactions. A study of patients with hand eczema, atopic dermatitis and controls. Acta Derm Venereol Suppl (Stockh) 1992; 173:1.
  45. Williams C, Wilkinson SM, McShane P, et al. A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use. Br J Dermatol 2010; 162:1088.
  46. Heese A, van Hintzenstern J, Peters KP, et al. Allergic and irritant reactions to rubber gloves in medical health services. Spectrum, diagnostic approach, and therapy. J Am Acad Dermatol 1991; 25:831.
  47. Pecquet C. Allergic contact dermatitis to rubber. Clinical aspects and main allergens. Clin Rev Allergy 1993; 11:413.
  48. Sussman G, Gold M. Guidelines for the management of latex allergies and safe latex use in health care facilities. Am College of Allergy Asthma and Immunology 1996. www.acaai.org/public/physicians/latex.htm (Accessed on January 16, 2009).
  49. Nettis E, Assennato G, Ferrannini A, Tursi A. Type I allergy to natural rubber latex and type IV allergy to rubber chemicals in health care workers with glove-related skin symptoms. Clin Exp Allergy 2002; 32:441.
  50. Tegner E, Thelin I. PUVA treatment of chronic eczematous dermatitis of the palms and soles. Acta Derm Venereol 1985; 65:451.
  51. Grattan CE, Carmichael AJ, Shuttleworth GJ, Foulds IS. Comparison of topical PUVA with UVA for chronic vesicular hand eczema. Acta Derm Venereol 1991; 71:118.
  52. Aoyama H, Tanaka M, Hara M, et al. Nummular eczema: An addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens. Dermatology 1999; 199:135.